Table 2.

Summary of efficacy results

Efficacy analysis set
(N = 120)
Primary endpoint
 ORR by IRC31 (25.8%)
  95% CI18.3–34.6
 CR13 (10.8%)
  95% CI5.9–17.8
 PR18 (15.0%)
  95% CI9.1–22.7
Secondary endpoints
 Median duration of response (n = 31)8.4 months
  95% CI4.5–29.4
 Median time to response (n = 31)5.6 weeks
  Range4.3–50.4
 Median time to progression (n = 120)2 months
  95% CI1.5–2.8